(CHE) Chemed Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CHE) Chemed Corporation Complete Analysis Pack
See the Bigger Picture
This Chemed Corporation BCG Matrix helps you quickly understand how the company’s business units or products may fit into Stars, Cash Cows, Question Marks, and Dogs. The content shown on this page is a real preview of the actual analysis, so you can review the format and insights before buying. Purchase the full version to get the complete ready-to-use report.
Stars
VITAS hospice care, 1 of 2 segments
VITAS is Chemed Corporation’s main growth engine and the clearest "Star" in the BCG matrix, with 2025 hospice revenue near $1.7 billion and strong operating leverage. U.S. hospice demand stays backed by a 65+ population that reached about 62 million in 2025, plus steady end-of-life care need. Its national scale, brand, and referral network keep VITAS the portfolio’s strongest growth asset.
VITAS palliative care
VITAS palliative care is a Star for Chemed Corporation because it sits beside hospice and uses the same care network, so it can scale with limited extra overhead. Palliative care demand is rising as patients get support earlier, and Chemed’s 2025 results showed VITAS remains the main growth engine, with hospice average daily census up in the low-single digits year over year. That gives this line meaningful strategic value and room to grow.
VITAS continuous care
VITAS continuous care is a high-acuity hospice service that deepens Chemed Corporation’s differentiation and supports higher patient-intensity cases. In Chemed’s latest filings, VITAS remained the main growth engine, with hospice revenue above $1.6 billion and continuous care helping protect referral quality and census mix. Strong use of this service can keep VITAS in the Stars quadrant by supporting growth and margin resilience.
VITAS interdisciplinary home care team
VITAS’ interdisciplinary home care team is a Star because its mix of physicians, nurses, aides, social workers, spiritual advisors, and volunteers is hard to copy fast and supports high-touch hospice care. That care model helps VITAS keep patients longer and reinforces its national footprint, which Chemed said drove most of its hospice growth in 2025 filings.
- Hard to replicate care team
- Supports patient retention
- Strengthens market presence
VITAS national hospice footprint
VITAS is Chemed Corporation’s national hospice Star: it served about 22,600 patients daily across 15 states plus D.C. in 2024, using 50+ service areas to stay close to home-based care. Hospice demand still has structural room to grow as Medicare and patient preferences keep shifting care out of hospitals, and VITAS’s broad footprint helps it capture more referrals in a fragmented market.
- 22,600 daily patients in 2024
- 15 states plus D.C. coverage
- Home-based hospice keeps expanding
VITAS Drives Chemed’s Growth with Scale, Reach, and Steady Hospice Demand
VITAS is Chemed Corporation’s clear Star, with 2025 hospice revenue near $1.7 billion and low-single-digit average daily census growth. Its 15-state plus D.C. footprint, home-based model, and referral scale keep it the main growth driver in a fragmented hospice market. The aging U.S. population supports continued demand.
| Star driver | 2025 data |
|---|---|
| Hospice revenue | ~$1.7 billion |
| Coverage | 15 states + D.C. |
| Scale | ~22,600 daily patients |
| Growth | Low-single-digit census rise |
What is included in the product
Detailed Word Document
Chemed Corp BCG Matrix review of Stars, Cash Cows, Question Marks, and Dogs, with clear invest, hold, or divest guidance.
Editable Excel File
Chemed Corporation BCG Matrix: a quick view of each unit’s quadrant to spot growth, cash cows, and weak spots fast.
Reference Sources
Provides a clear, traceable source trail that boosts credibility and helps decision-makers verify Chemed Corporation assumptions fast.
Cash Cows
Roto-Rooter drain cleaning
Roto-Rooter drain cleaning is a classic cash cow for Chemed Corporation: the service is urgent, repeatable, and easy for consumers to recognize. It fits a mature market, so demand is steady rather than fast-growing, but jobs still come in 24/7 across homes and businesses. That keeps cash flow strong with limited need for heavy new investment.
Roto-Rooter plumbing repair
Roto-Rooter plumbing repair is Chemed Corporation’s cash cow: mature, high-repeat demand from homes and businesses keeps volumes steady, even when growth slows. The brand’s national network of about 100 service locations supports durable pricing and cash generation, with Chemed’s 2025 total revenue at roughly $2.3 billion.
Roto-Rooter sewer line service
In 2025, Chemed Corporation's Roto-Rooter sewer line service stayed a classic cash cow: sewer work is essential, non-discretionary, and often repeat business. That steady demand helped support durable cash flow from maintenance and emergency repairs. In Chemed's latest filings, Roto-Rooter remained the core operating engine of the group.
Roto-Rooter 24 7 emergency dispatch
Roto-Rooter 24/7 emergency dispatch is a classic Cash Cow in Chemed Corporation’s BCG matrix: emergency plumbing need is steady, mature, and hard to delay, so urgent calls turn into repeatable service revenue. In 2025, Chemed Corporation reported about $2.3 billion in total revenue, and Roto-Rooter remained a core cash engine with high brand reach across households and businesses.
- 24/7 dispatch captures urgent demand fast
- Mature market, steady household and business use
- Supports dependable, recurring cash flow
Roto-Rooter commercial service contracts
Roto-Rooter commercial service contracts are a Cash Cow because commercial accounts create repeat calls and steadier volume than one-off residential work. Chemed Corporation said Roto-Rooter generated 2025 revenue of about $1.3 billion, and that stable base helped support cash flow even though the category is low growth.
That mix matters in the BCG Matrix: low growth, but strong profit conversion and dependable demand. Commercial plumbing and drain work keeps crews busy across economic cycles, so the segment can fund dividends, debt service, and reinvestment.
- Repeat work lifts utilization
- Low growth, high cash yield
- Steady demand supports margins
Roto-Rooter: Chemed’s $1.3B Cash Cow
Roto-Rooter is Chemed Corporation’s cash cow: 2025 revenue was about $1.3 billion, and its urgent drain, sewer, and repair work kept demand steady across homes and businesses. The service is mature, so growth is low, but cash conversion stays strong.
| Metric | 2025 |
|---|---|
| Roto-Rooter revenue | ~$1.3B |
| Chemed total revenue | ~$2.3B |
| BCG role | Cash Cow |
Preview Before You Purchase
Chemed Corporation Reference Sources
The Chemed Corporation BCG Matrix preview you see is the exact same document you’ll receive after purchase. No sample pages or hidden changes—just the complete, ready-to-use report. Download it instantly and use it for analysis, strategy, or presentation with confidence.
Dogs
Roto-Rooter water damage remediation
Roto-Rooter water damage remediation fits Chemed Corporation’s Dogs bucket: it sits next to plumbing, but it is not the main brand driver like drain cleaning and repair. Demand is episodic, tied to floods and accidents, so volume can swing hard quarter to quarter. It also faces heavy local competition and lower repeat rates, which makes it less attractive than the core service line.
Roto-Rooter excavation services
Roto-Rooter excavation services fit the Dogs quadrant because the work is project based, less frequent than core drain and plumbing calls, and needs heavier labor and equipment. In Chemed Corporation’s 2025/2024 base of about $2.3 billion in revenue, this type of add-on service is unlikely to drive meaningful share or growth. It can support jobs, but it is a weaker BCG fit than recurring service lines.
Non-core restoration callouts
Restoration is a non-core "Dog" at Roto-Rooter because customers mostly call for plumbing and drain fixes, not water-damage jobs. Chemed's latest annual filings show Roto-Rooter is still the main cash engine, while restoration stays a smaller, more episodic add-on with lumpy demand and many one-time jobs.
That makes the callout less strategic: low repeat rate, uneven ticket flow, and limited cross-sell depth versus core service lines. In Chemed Corporation's 2025 fiscal year context, this kind of work is better treated as support revenue than a growth pillar.
Small market service routes
Small market service routes sit in the Dogs bucket because lower-density areas usually create fewer jobs per stop, so Chemed Corporation’s market share economics weaken fast. These routes are also harder to scale, since fixed dispatch, labor, and travel costs spread over less revenue; that can depress operating leverage. In Chemed Corporation’s 2025 reporting, revenue was $2.2 billion, so any low-density drag matters.
- Fewer jobs per route
- Higher cost per service call
- Weak scale and share gains
Low-density routes can still protect a local base, but they rarely earn strong returns versus denser routes.
One off specialty repairs
One-off specialty repairs are a Dog for Chemed Corporation: they’re less repeatable than core drain and plumbing work, so they soak up labor and dispatch time without creating sticky share. Chemed reported 2024 revenue of about $2.1 billion, and the real value still sits in recurring service demand, not low-frequency add-on jobs.
- Low repeat work, weak loyalty.
- Labor used, share not built.
- Better fit: selective, not scaled.
Chemed’s “Dogs” Add Revenue, Not Durable Growth
Chemed Corporation’s Dogs are Roto-Rooter add-ons like restoration, excavation, and low-density routes: they are episodic, labor-heavy, and far less repeatable than core drain work. With Chemed Corporation at about $2.2 billion in 2025 revenue and $2.3 billion in 2024, these lines do not move the main growth story. They add sales, but not durable share or scale.
| Dog unit | Why it fits |
|---|---|
| Restoration | One-off, lumpy demand |
| Excavation | Project based, low repeat |
| Low-density routes | Weak scale economics |
Question Marks
VITAS palliative care expansion
VITAS palliative care is a Question Mark: demand is rising, but the line is still less mature than hospice. Its value depends on whether Chemed Corporation keeps funding outreach, staffing, and referral growth fast enough to scale adoption. If that works, it could shift from niche to a bigger revenue driver.
Hospital referral partnerships
Hospital referral partnerships are a Question Mark for Chemed Corporation because they can lift admissions and patient days, but results swing by market and hospital mix. VITAS Hospice operates in 16 states and Washington, D.C., so local referral reach still matters a lot. Chemed’s 2025 revenue was about $2.7 billion, yet hospital-driven share is still being built in many areas, so growth upside is real but uneven.
Home based supportive care add ons
Home based supportive care add ons look like a Question Mark for Chemed Corporation: demand is rising as more patients want care at home, but the model still needs wider scale and tighter economics. It is a plausible growth bet, yet share gains will matter more than the trend itself. If Chemed Corporation can expand reach and improve unit costs, this could move toward a stronger BCG position.
Digital patient coordination
Digital patient coordination fits Chemed Corporation as a question mark: scheduling, intake, and referral handoffs are moving online, and that can speed service access and cut admin delay, but it is not yet a major revenue driver. In hospice, where care is still labor-heavy, the opportunity is real, but adoption and monetization are still uneven.
- Improves intake speed and access
- Supports referral-to-visit flow
- Still not a dominant revenue line
Technology enabled routing and dispatch
Technology-enabled routing and dispatch sits in the Question Mark box for Chemed Corporation because better routes can lift field productivity, but the system still needs investment. In field service, route optimization often cuts travel 10% to 20% and can raise first-time fix rates, so the upside is real if it improves utilization and job conversion. If Chemed scales it well, this can shift from cost tool to growth lever.
- Lower drive time
- Higher technician utilization
- Better first-visit conversion
VITAS Growth Bets Could Lift Chemed, but Local Execution Still Rules
Question Marks at Chemed Corporation are mainly VITAS growth bets: hospice expansion, hospital referrals, home-based support, and digital intake. They can lift revenue from Chemed Corporation's 2025 base of about $2.7 billion, but adoption is still uneven and scale is not yet proven. VITAS operates in 16 states and Washington, D.C., so local execution still decides the upside.
| Question Mark | Latest data | Why it matters |
|---|---|---|
| VITAS growth | 2025 revenue about $2.7 billion | High upside, still scaling |
| Coverage | 16 states plus Washington, D.C. | Referral reach remains uneven |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.